SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL SPIRO COMPOUNDS CONTAINING THIAZOLIDINONE AND 1,3,4-OXADIAZOLE MOIETIES

Authors

  • Aluru Raghavendra Guru Prasad ICFAI Foundation for Higher Education, Hyderabad, A.P. India
  • Kakarlapudi Ranga Raju Sri Krishnadevaraya University, Anantapur, A.P., India.
  • Badampudi Santosh Kumar Sri Krishnadevaraya University, Anantapur, A.P., India.
  • Lakshmana Rao Krishna Rao Ravindranath 1Sri Krishnadevaraya University, Anantapur, A.P., India.

DOI:

https://doi.org/10.5457/ams.v44i1-2.328

Keywords:

Synthesis, characterisation, thiazolidinone, 1, 3, 4-oxadiazole, antimicrobial activity.

Abstract

Introduction: During recent years, the microorganisms have developed resistance to the drugs. Therefore, there is an ever raising demand for new, potent, fast-acting antimicrobial drugs with low toxicity. Thiazolidinone and 1,3,4-oxadiazole nuclei have been incorporated  into wide variety of drugs  leading to wide spectrum of pharmacological activity.

 

Aim: To describe the synthetic strategy and structural characterization of some novel spiro compounds containing thiazolidinone and 1,3,4-oxadiazole moieties and pertaining antimicrobial evaluation. Structural characterization was done based on the elemental analysis, IR spectral, 1H NMR spectral and 13C NMR spectral data. The antimicrobial activity of the newly synthesized compounds were evaluated by cup plate method.

 

Conclusion: The spiro compounds with -OCH3, -Cl and -Br substituents, namely 7c, 7e and 7f displayed promising in-vitro antimicrobial activity.

Author Biography

Aluru Raghavendra Guru Prasad, ICFAI Foundation for Higher Education, Hyderabad, A.P. India

Academic Coordinator, Faculty of Science and Technology, IFHE.

Published

2016-09-07

Issue

Vol. 44 No. 1-2 (2015)

Section

Original papers

License

Copyright transfer

The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.